Collaborations

Key partners in our science

Vyriad partners with leading medical institutions and pharmaceutical companies to advance the development of our oncolytic virus technologies.  The company has an extensive research collaboration with Regeneron Pharmaceuticals, Inc. to develop Voyager-V1 and the next generation of fully retargeted VSV-based oncolytic virus therapies.

Regeneron Logo

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Vyriad and Regeneron have entered into a strategic research collaboration that includes a Phase 2 study of Voyager-V1 and Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab-rwlc) in multiple cancer indications. The companies also plan to join forces to design and novel Vesicular Stomatitis Virus (VSV)-based oncolytic virus treatments.

EMD Serono Logo

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases.

Vyriad and EMD Serono have a clinical research agreement to evaluate Voyager-V1 and Bavencio® (avelumab), an anti-PD-L1 antibody, as a combination therapy for metastatic colorectal cancer.

Mayo Clinic  Logo

Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing.

Vyriad and Mayo Clinic have a clinical research agreement to study the combination of Voyager-V1 and Keytruda® (pembrolizumab), Merck’s an anti-PD-1 antibody, in non-small cell lung cancer and squamous cell carcinoma of the head and neck.

University of California, San Francisco (UCSF)  Logo

The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

UCSF and PNOC are conducting a Phase 1 study to assess the safety and efficacy of Vyriad’s modified measles virus in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor.

Pacific Pediatric Neuro-Oncology Consortium (PNOC)  Logo

The Pacific Pediatric Neuro-Oncology Consortium (PNOC) was formed to provide children with brain tumors access to innovative treatments. What sets us apart is that we pursue clinical strategies that are based on the molecular and genetic make-up of each tumor.

UCSF and PNOC are conducting a Phase 1 study to assess the safety and efficacy of Vyriad’s modified measles virus in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor.

Interested in partnering with Vyriad?

Vyriad works closely with researchers and clinicians at major pharmaceutical companies, leading universities, government institutions, and medical research centers around the world. Researchers interested in a preclinical or clinical collaboration with Vyriad are welcome to contact us.